A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.

MLA

San-Miguel, Jesús F., et al. “A Phase I/II Dose-Escalation Study Investigating All-Oral Ixazomib-Melphalan-Prednisone Induction Followed by Single-Agent Ixazomib Maintenance in Transplant-Ineligible Newly Diagnosed Multiple Myeloma.” Haematologica, vol. 103, no. 9, Sept. 2018, pp. 1518–26. EBSCOhost, https://doi.org/10.3324/haematol.2017.185991.

APA

San-Miguel, J. F., Echeveste Gutierrez, M.-A., Špicka, I., Mateos, M.-V., Song, K., Craig, M. D., Bladé, J., Hájek, R., Chen, C., Di Bacco, A., Estevam, J., Gupta, N., Byrne, C., Lu, V., van de Velde, H., & Lonial, S. (2018). A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. Haematologica, 103(9), 1518–1526. https://doi.org/10.3324/haematol.2017.185991

Chicago

San-Miguel, Jesús F, Maria-Asunción Echeveste Gutierrez, Ivan Špicka, María-Victoria Mateos, Kevin Song, Michael D Craig, Joan Bladé, et al. 2018. “A Phase I/II Dose-Escalation Study Investigating All-Oral Ixazomib-Melphalan-Prednisone Induction Followed by Single-Agent Ixazomib Maintenance in Transplant-Ineligible Newly Diagnosed Multiple Myeloma.” Haematologica 103 (9): 1518–26. doi:10.3324/haematol.2017.185991.